Bertozzi’s click chemistry could be key for allogeneic cell therapies

The past decade has brought a shift in the use of click chemistry from basic science to clinical translation, and the method, which was invented by 2022 Nobel Prize winner Carolyn Bertozzi, could turn out to be particularly important for the success of allogeneic cell therapies.

Bertozzi, who on Monday joined allogeneic immune cell company Acepodia Inc. (TPEx:6976) as chief scientific adviser, won the Nobel Prize in Chemistry last year for developing “click chemistry and bio-orthogonal chemistry.” She shared the prize with University of Copenhagen Professor Morten Meldal and Scripps Research Professor K. Barry Sharpless...